bluebird bio, Inc.
BLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.75 | 0.81 | 0.93 |
| FCF Yield | -325.00% | -12.40% | -3.37% | -4.78% |
| EV / EBITDA | -2.40 | -12.43 | -51.63 | -24.59 |
| Quality | ||||
| ROIC | -82.57% | -46.50% | -51.44% | -121.37% |
| Gross Margin | -6.65% | -13.66% | -180.15% | -961.09% |
| Cash Conversion Ratio | 1.08 | 1.11 | 1.32 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 185.61% | 100.46% | -75.70% | -56.56% |
| Free Cash Flow Growth | -7.59% | 33.33% | 44.41% | -31.90% |
| Safety | ||||
| Net Debt / EBITDA | -1.89 | -0.65 | -1.18 | 0.13 |
| Interest Coverage | -11.98 | -14.94 | -39.57 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.37 | 1.46 | -7.13 | -0.40 |
| Cash Conversion Cycle | 198.16 | 209.11 | 504.88 | -20.19 |